.jpeg/jcr:content/renditions/cq5dam.web.1200.Rare-Disease-TA-Visual-Landscape-RGB-hero-(1).jpeg)
Rare Disease
Home / 澳门第一赌城在线娱乐的治疗领域 / Rare Disease
澳门第一赌城在线娱乐的承诺
澳门第一赌城在线娱乐的使命是改变罕见病患者的生活. 通过了解患者的独特需求, 澳门第一赌城在线娱乐可以研究和开发创新药物, 支持获取和倡导罕见病社区.
澳门第一赌城在线娱乐认为倾听是澳门第一赌城在线娱乐的责任, understand, and change the lives of patients and those who work tirelessly to help them. 澳门第一赌城在线娱乐的创新始于了解患有罕见疾病的人, 是什么推动了澳门第一赌城在线娱乐所有的努力.
未满足的医疗需求和世界市场
400 million
>7,000
十分之三的儿童
澳门第一赌城在线娱乐在罕见病方面的策略
Alexion’s pioneering legacy in rare diseases is rooted in being the first to translate the complex biology of the complement system into transformative medicines. 通过推动创新研究和开发(R&D)跨越新的疾病目标和模式, we have diversified our pipeline into additional rare diseases over the last several years. Today, 作为澳门在线赌城娱乐的一部分, we are building bridges across our scientific platforms with a focus on bringing more innovative medicines to people worldwide.
澳门第一赌城在线娱乐的罕见病战略侧重于三个核心优先事项:
1. Accelerate by creating smart and efficient strategies to speed access to our medicines for patients.
2. 通过科学投资进行创新, 平台和功能, 包括使用澳门第一赌城在线娱乐自己的技术和研究能力.
3. Reach beyond our current geographic footprint to as many rare disease patients as possible.
Our R&D approach
For 30 years, Alexion’s pioneering science has led to the development of transformational medicines for rare diseases, 今天，澳门第一赌城在线娱乐继续引领这一潮流. Our success is tied to listening, to understanding, and responding to the communities we serve.
Rare disease R&D presents unique challenges that require continuous innovation to deliver meaningful medicines for patients. Driven by our patient-centric approach, we pave the way by tailoring elements of the R&D process and developing new tools and methods to gain a deeper understanding of many rare conditions and the needs of the people living with them.
Our people
We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. 澳门第一赌城在线娱乐所做的一切, we are empowered and committed to speak up and perform at our personal best to accelerate our collective impact for people living with rare diseases. 澳门第一赌城在线娱乐的文化植根于诚信, inclusiveness, and our dedication to joining and supporting the communities in which we live and work.
我很高兴能与Alexion的同事一起发现, develop and deliver medicines that change the lives of people suffering from rare diseases. We also look forward to applying Alexion’s complement biology platform across areas of AstraZeneca’s broader early-stage pipeline, and to making our rare disease medicines available to patients in many countries where AstraZeneca has a strong presence.
Join our team
澳门第一赌城在线娱乐是创新者、领导者和合作者. And at the heart of everything we do is an intense desire to pursue the toughest challenges and truly change the world for people living with rare and devastating diseases.
Our medicines
We cannot provide detailed information about our prescription medicines on this website, 遵守规定.
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, 有时是任何, information on our prescription medicines so you should seek alternative trustworthy sources. 一定要向医疗保健专业人员咨询有关药物的建议.
Kanuma
sebelipase阿尔法
Soliris
eculizumab
Strensiq
asfotase alfa
Ultomiris
ravulizumab
澳门第一赌城在线娱乐的罕见病产品线
每天都在推进澳门第一赌城在线娱乐的管道
We’re building on our fundamental understanding of complement biology and advancing on our core therapy areas of haematology, nephrology, neurology, metabolics, and cardiology. We continue to evolve into new areas where there is a great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives.
罕见病(截至2023年11月9日)
Phase 1
Phase 1
Phase 2
Phase 3
Phase 3
LCM Projects
Latest news
Veeva ID: Z4-50908
筹备日期:2022年11月